News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,697 Results
Type
Article (43341)
Company Profile (474)
Press Release (688877)
Multimedia
Podcasts (112)
Webinars (20)
Section
Business (209178)
Career Advice (2033)
Deals (36107)
Drug Delivery (111)
Drug Development (83863)
Employer Resources (174)
FDA (16620)
Job Trends (15171)
News (353815)
Policy (33246)
Tag
Academia (2648)
Accelerated approval (22)
Adcomms (28)
Allergies (126)
Alliances (51109)
ALS (152)
Alzheimer's disease (1652)
Antibody-drug conjugate (ADC) (262)
Approvals (16744)
Artificial intelligence (466)
Autoimmune disease (111)
Automation (32)
Bankruptcy (373)
Best Places to Work (11842)
BIOSECURE Act (20)
Biosimilars (166)
Biotechnology (331)
Bladder cancer (141)
Brain cancer (52)
Breast cancer (533)
Cancer (4242)
Cardiovascular disease (361)
Career advice (1715)
Career pathing (35)
CAR-T (249)
CDC (44)
Cell therapy (672)
Cervical cancer (32)
Clinical research (70487)
Collaboration (1465)
Company closure (4)
Compensation (999)
Complete response letters (53)
COVID-19 (2746)
CRISPR (89)
C-suite (661)
Cystic fibrosis (142)
Data (5308)
Decentralized trials (2)
Denatured (36)
Depression (115)
Diabetes (448)
Diagnostics (6633)
Digital health (39)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (215)
Drug pricing (174)
Drug shortages (29)
Duchenne muscular dystrophy (213)
Earnings (90957)
Editorial (52)
Employer branding (21)
Employer resources (152)
Events (119929)
Executive appointments (965)
FDA (19260)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (21)
Funding (1329)
Gene editing (191)
Generative AI (34)
Gene therapy (559)
GLP-1 (943)
Government (4714)
Grass and pollen (6)
Guidances (375)
Healthcare (19191)
HIV (49)
Huntington's disease (40)
IgA nephropathy (78)
Immunology and inflammation (244)
Immuno-oncology (24)
Indications (68)
Infectious disease (2987)
Inflammatory bowel disease (186)
Inflation Reduction Act (16)
Influenza (100)
Intellectual property (203)
Interviews (315)
IPO (16903)
IRA (51)
Job creations (3711)
Job search strategy (1439)
Kidney cancer (15)
Labor market (78)
Layoffs (574)
Leadership (30)
Legal (8018)
Liver cancer (89)
Longevity (12)
Lung cancer (606)
Lymphoma (306)
Machine learning (33)
Management (59)
Manufacturing (649)
MASH (158)
Medical device (13816)
Medtech (13851)
Mergers & acquisitions (20140)
Metabolic disorders (1151)
Multiple sclerosis (142)
NASH (19)
Neurodegenerative disease (262)
Neuropsychiatric disorders (70)
Neuroscience (2742)
NextGen: Class of 2025 (6767)
Non-profit (4567)
Now hiring (59)
Obesity (539)
Opinion (267)
Ovarian cancer (147)
Pain (163)
Pancreatic cancer (185)
Parkinson's disease (252)
Partnered (29)
Patents (429)
Patient recruitment (359)
Peanut (54)
People (59841)
Pharmaceutical (86)
Pharmacy benefit managers (26)
Phase I (22133)
Phase II (31083)
Phase III (23001)
Pipeline (3454)
Policy (271)
Postmarket research (2602)
Preclinical (9530)
Press Release (67)
Prostate cancer (213)
Psychedelics (50)
Radiopharmaceuticals (277)
Rare diseases (693)
Real estate (6054)
Recruiting (70)
Regulatory (24233)
Reports (51)
Research institute (2463)
Resumes & cover letters (353)
Rett syndrome (20)
RNA editing (16)
RSV (72)
Schizophrenia (138)
Series A (216)
Series B (166)
Service/supplier (11)
Sickle cell disease (86)
Special edition (25)
Spinal muscular atrophy (157)
Sponsored (37)
Startups (3792)
State (2)
Stomach cancer (17)
Supply chain (98)
Tariffs (80)
The Weekly (74)
Vaccines (950)
Venture capital (72)
Weight loss (355)
Women's health (69)
Worklife (18)
Date
Last 7 days (391)
Last 30 days (3205)
Last 365 days (31138)
2025 (28979)
2024 (36301)
2023 (41016)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (752)
Alabama (80)
Alaska (7)
Arizona (290)
Arkansas (14)
Asia (40279)
Australia (6699)
California (10247)
Canada (3025)
China (948)
Colorado (428)
Connecticut (458)
Delaware (289)
Europe (88405)
Florida (1497)
Georgia (324)
Hawaii (2)
Idaho (61)
Illinois (773)
India (53)
Indiana (478)
Iowa (21)
Japan (346)
Kansas (126)
Kentucky (37)
Louisiana (25)
Maine (70)
Maryland (1311)
Massachusetts (7523)
Michigan (296)
Minnesota (579)
Mississippi (5)
Missouri (119)
Montana (32)
Nebraska (26)
Nevada (109)
New Hampshire (78)
New Jersey (2790)
New Mexico (30)
New York (2727)
North Carolina (1402)
North Dakota (9)
Northern California (4844)
Ohio (299)
Oklahoma (20)
Oregon (41)
Pennsylvania (2109)
Puerto Rico (19)
Rhode Island (45)
South America (1114)
South Carolina (56)
South Dakota (1)
Southern California (3953)
Tennessee (158)
Texas (1567)
United States (36868)
Utah (304)
Vermont (1)
Virginia (242)
Washington D.C. (79)
Washington State (845)
West Virginia (4)
Wisconsin (89)
Wyoming (2)
732,697 Results for "carmot therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Carmot Therapeutics Announces Completion of Acquisition by Roche
Carmot Therapeutics Inc. today announced that its acquisition by the Roche Group (Roche) has been completed.
January 29, 2024
·
3 min read
Weight loss
Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy
Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Roche will speed up the development of its obesity programs, seeking to differentiate itself in the market.
July 26, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche’s oral GLP-1 receptor agonist CT-996—obtained in the $2.7 billion acquisition of Carmot Therapeutics—reduced body weight by more than 6% at four weeks versus placebo in a Phase I trial.
July 17, 2024
·
2 min read
·
Tristan Manalac
Obesity
Roche Drops Early Obesity Asset, Citing Lack of Competitiveness
Roche obtained CT-173, a PYY mimetic, in its $2.7 billion acquisition of Carmot Therapeutics in December 2023. The company reported the change in its second quarter earnings call.
July 24, 2025
·
2 min read
·
Tristan Manalac
Business
Carmot Therapeutics Appoints Charles W. Newton to Board of Directors
Carmot Therapeutics, Inc. today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.
July 19, 2023
·
2 min read
Drug Development
Roche Sees Early ROI on $2.7B Carmot Buy with Phase I Data for Obesity Candidate
Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational GLP-1/GIP receptor agonist induced strong weight loss in a Phase Ib study.
May 16, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Zevra Therapeutics, Inc. Announces CFO Transition
November 21, 2025
·
3 min read
Deals
Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
November 20, 2023
·
2 min read
·
Tristan Manalac
Deals
Roche Jumps into Lucrative Weight-Loss Space with $2.7B Carmot Buy
The acquisition will give Roche access to Carmot’s clinical portfolio of three GLP-1 receptor agonists, placing it squarely in the middle of the competition to treat overweight and obesity.
December 4, 2023
·
2 min read
·
Tristan Manalac
Drug Development
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes
Carmot Therapeutics Inc. today announced that it has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult participants with overweight or obesity with T1D.
November 15, 2023
·
4 min read
1 of 73,270
Next
